ADC biotech LyncBio Therapeutics raises ~¥100M in Pre-A round to advance autoimmune & oncology pipelines

Recently, LyncBio Therapeutics, a Chinese biotech startup focused on innovative drug R&D for autoimmune diseases and antibody-drug conjugates (ADCs), successfully completed a nearly 100 million yuan Pre-A funding round. This round was jointly led by Panlin Capital and Apricot Capital. The proceeds will be primarily allocated to advance the clinical trials of the company's core product by 2026 and to expand its pipeline.

Prior to this, LyncBio Therapeutics had already secured tens of millions of RMB in a seed funding round, which was led by Apricot Capital, an investment firm specializing in the life sciences sector.

Founded in September 2023, LyncBio Therapeutics leverages its proprietary core ADC technology platform to achieve rapid progress in its key pipeline for intestinal inflammation treatment. The company has independently developed the ADC candidate, completed GMP manufacturing and toxicology studies within two years, and is currently in the IND application stage, showing promise to fill a clinical gap for ADC therapies in this specific treatment area internationally.

Simultaneously, the company's pipeline includes several other investigational products in early-stage development, covering indications such as multiple sclerosis, pan-cancer solid tumors, and multiple myeloma. This forms a strategic layout characterized by "leadership in next-generation bispecific ADC technology, complemented by synergistic development of multiple pipelines."

Following this funding round, LyncBio Therapeutics will further increase its R&D investment to accelerate the advancement of its lead program into clinical trials, while continuing early-stage research on multiple novel ADCs. Regarding team development, the company will persistently attract top-tier industry talent to build a comprehensive talent structure, thereby rapidly enhancing overall R&D innovation capabilities and operational efficiency. In terms of external collaboration, LyncBio will prioritize business development, engaging in deep discussions with international multinational corporations (MNCs) and leading investment institutions to actively explore potential investment and project partnership opportunities.